Monitor the December 11, 2026 stockholder approval deadline for Series A conversion and potential $51.9M cash settlement risk. Track any milestone warrant exercise announcements for up to $32.4M in additional funding. The next catalyst is the AT177 IND submission in H1 2027.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $4.09entry
- T+1 · yesterday −6.85%α −4.93% · $3.81
- T+2 · todayOpen
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Azora Therapeutics (formerly Adial Pharmaceuticals) reported Q3 2026 results post-merger: net loss of $64.6M ($4.52 per share) vs $1.8M ($2.02 per share) a year ago, driven by a $57.1M non-cash fair value charge on milestone warrant rights. Cash burn was $6.7M QoQ to $22.0M. The company is now trading as AZR on Nasdaq with a new CEO, CFO, and board. AT177 IND submission and Phase 1a remain on track for H1 2027. No consensus estimates were provided for comparison.
Key Financial Metrics
Key Facts
- Net loss of $64.6M ($4.52 per share) for Q3 2026, including a $57.1M non-cash charge for change in fair value of milestone warrant rights liability
- Cash and cash equivalents $22.0M as of September 30, 2026, down from $28.7M at June 30, 2026
- R&D expenses increased to $1.8M from $0.5M year-over-year; G&A expenses increased to $5.8M from $1.2M
- Company changed name from Adial Pharmaceuticals to Azora Therapeutics and began trading as AZR on Nasdaq on October 29, 2026
- New executive team and board appointed; 9.9M shares of Series A preferred converted to common stock on November 2, 2026
- AT177 IND submission and Phase 1a trial planned for first half of 2027
- Up to $32.4M in potential gross proceeds from milestone warrant purchases if investors elect to exercise
- Stockholders' deficit of $21.1M as of September 30, 2026, primarily due to $38.5M Series A preferred classified as temporary equity
Financial Impact
Net loss of $64.6M in Q3 2026, cash burn of $6.7M from $28.7M to $22.0M during the quarter
Risk Factors
- Stockholders' deficit of $21.1M and going concern risk; company may need additional capital before AT177 reaches clinical data
- Potential $51.9M cash settlement obligation if stockholder approval for Series A conversion is not obtained by December 11, 2026
- Massive potential dilution from up to 25.1M shares registered for resale (nearly 10x current shares outstanding) per the S-3/A filed October 20, 2026
- Nasdaq delisting risk remains unresolved; material weakness in internal control over financial reporting identified
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-118922 |
| Document: ea0311952-8k_azora.htm | 0001213900-26-118922 |
| Document: 0001213900-26-118922-index-headers.html | 0001213900-26-118922 |
| Document: 0001213900-26-118922-index.html | 0001213900-26-118922 |
| Document: 0001213900-26-118922.txt | 0001213900-26-118922 |
| 8-K Data (Synthetic) | 0001213900-26-118922 |
Track record
5 reports on AZR
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today S-3 Bearish 6/10 Entry $3.81 Now $3.66 +3.81% settles Nov 24
- Nov 12, 20265d ago 8-K Neutral 4/10 Viewing Entry $4.09 Now $3.66 −10.39% settles Nov 20
- Nov 10, 20267d ago 3 Neutral 2/10 Entry $3.76 to $3.67 Now $3.66 −2.53% ▼ −2.53% −0.20% vs SPY
- Nov 9, 20268d ago 8-K Neutral 4/10 Entry $3.75 to $3.81 Now $3.66 −2.27% ▲ +1.60% +3.29% vs SPY
- Nov 3, 202614d ago SC 13G/A Bearish 4/10 Entry $4.15 to $3.76 Now $3.66 +11.69% ▲ +9.40% +8.81% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers